# Benchmarking retention and adherence across therapeutic areas
A patient fills a 90-day statin prescription in January. By month four, roughly 4 in 10 patients like her have quietly stopped, no phone call, no complaint, just an empty bottle and a lapsed refill. Cardiovascular drugs lose almost half their patients to non-adherence within a year. Meanwhile, some oral oncology brands hold 80%+ of patients through an entire treatment course. Same industry, wildly different retention physics. If you benchmark your brand against "pharma average," you'll draw the wrong conclusion almost every time.
This lesson gives you the vocabulary and reference points to judge whether your refill, persistence, and switch-back numbers are actually good, or just look good in a slide.
Retention in pharma marketing is not one number. It's shaped by disease severity, dosing burden, side-effect profile, cost-sharing, and whether a physician or patient drives the refill decision.
Three core metrics recur across the sector:
A PDC threshold of 80% is the industry-standard cutoff for "adherent," used by CMS Star Ratings and most pharmacy benefit managers (PBMs, the intermediaries like CVS Caremark or Express Scripts that manage drug benefits for insurers).
These are directional estimates drawn from published adherence literature and PBM/claims-based studies, not a single brand's confidential data. Treat ranges, not point figures, as the benchmark.
| Therapeutic area | Typical 1-year PDC ≥80% rate | Typical 1-year persistence | Why |
|---|---|---|---|
| Oral oncology (e.g., CML, breast cancer) | ~70-85% | High, often 12+ months | High stakes, close physician monitoring, patient support programs |
| Diabetes (oral, non-insulin) | ~50-65% | Moderate, drop-off at 6-12 months | Asymptomatic disease, cost sensitivity, polypharmacy fatigue |
| Statins/cardiovascular | ~50-60% | ~50% discontinue by 12 months | Asymptomatic, "silent" benefit, side-effect concerns |
| Dermatology (topical, chronic, e.g., psoriasis) | ~40-55% | Often under 6 months for topicals | Visible but non-fatal condition, application burden, cosmetic tolerance issues |
| Biologics (injectable, immunology/rheumatology) | ~65-80% | Higher, often 12+ months | High efficacy visibility, hub services, high switching cost |
Sources for directional ranges: published adherence reviews summarized by NCBI/PubMed adherence literature and CMS Star Ratings technical notes. Always re-verify against the specific drug class and most recent claims data before using in a real benchmarking exercise.
Read the pattern: adherence tracks with visibility of disease consequence and support infrastructure, not with drug efficacy alone. Dermatology topicals underperform not because they don't work, but because patients feel better before the label says to stop.
Say your dermatology brand (an oral, once-daily systemic for moderate-to-severe psoriasis) reports:
Step 1: Calculate the adherent rate.
Adherent rate = Adherent patients / Total patients
= 2,600 / 5,000
= 52%Step 2: Compare against the benchmark band for your category. Oral systemics for psoriasis sit closer to the biologics/oncology end of dermatology (higher disease severity, specialist-monitored) rather than topical creams. A reasonable comparison band might be 55-70%, not the 40-55% topical range.
Step 3: Conclusion. At 52%, you're slightly below a fair comparison band, not "average for dermatology" as a lazy benchmark would suggest. That gap is your actionable signal, not a footnote.
This is the single most common benchmarking error in pharma marketing decks: comparing an oral systemic against "dermatology" as a monolith when the real comparator set should be disease severity and route of administration, not therapeutic area label alone.
Switch-back rate matters because a raw discontinuation number overstates true brand loss. If a patient switches to a generic during a formulary exclusion (when a PBM removes a drug from its covered list) and returns once your brand is reinstated, that's not attrition, it's friction.
Switch-back rate = Patients returning to brand within 12 months /
Patients who discontinued brandA high switch-back rate (commonly cited informally in pharma commercial analytics as 15-25% for brands with strong patient support hubs) tells you retention economics are healthier than raw persistence curves suggest. It also justifies investment in patient hub services, the manufacturer-funded programs providing nurse support, copay assistance, and reminder systems, because they preserve the "on-ramp back" even after a lapse.
Adherence measurement is less standardized across the EU because pharmacy claims infrastructure is fragmented by country and much of primary care runs through public systems (NHS in the UK, statutory health insurance in Germany) rather than PBM claims databases like in the US. Persistence studies do exist (published via national health registries and organizations like the European Medicines Agency) but comparable PDC benchmarking is harder to source publicly and generally runs on a lag. Treat any EU adherence figure you see as a study-specific estimate, not a real-time operational benchmark, and be explicit about that caveat when presenting to stakeholders.
Vérification des acquis
1. Why does benchmarking a brand's retention against a generic 'pharma average' tend to produce misleading conclusions?
2. A patient stops filling her cardiovascular medication in month four but had been taking it exactly as prescribed while she was on it. Which metric captures the fact that she discontinued, as distinct from how well she followed dosing while on therapy?
3. A brand shows a drop in refills for a competitor drug that later rebounds as many of those patients return to the original brand within two months. What does a high switch-back rate in this scenario most likely indicate?
4. Select ALL correct answers about factors that explain why retention 'physics' differ across therapeutic areas.
Sélectionnez toutes les réponses correctes.
5. Select ALL correct answers about the PDC (Proportion of Days Covered) metric.
Sélectionnez toutes les réponses correctes.
Once you know where your brand sits relative to a fair comparator band, three levers typically move retention:
1. Reduce friction at refill: 90-day fills and auto-refill enrollment measurably lift PDC versus 30-day fills, because each fill is a re-decision point for the patient.
2. Invest in hub services proportional to disease burden: biologics and oncology brands with white-glove onboarding and nurse check-ins consistently outperform their category's baseline persistence.
3. Segment your churn: separate "lapsed due to side effects," "lapsed due to cost," and "lapsed due to formulary" cohorts. Each needs a different marketing and market access response, cost-driven lapses respond to copay cards, side-effect lapses need earlier physician follow-up messaging, not a discount.
🎬 [VIDEO: "Medication Adherence: Why Patients Don't Take Their Medicine" - youtube.com - a clinician-oriented explainer on the drivers of non-adherence, useful context for why marketing levers only solve part of the problem]